Abstract:Background: Late-life depression, often accompanied by cognitive impairment, poses significant clinical challenges owing to its complex etiology and diverse manifestations. While antidepressants like venlafaxine and anxiolytics such as buspirone are effective for treating depression, their effects on cognitive function remain less well-understood. With the aging population increasingly experiencing geriatric depression, there is an urgent need for innovative treatment approaches that address both depressive symptoms and cognitive impairments. Objective: This study aimed to evaluate the clinical efficacy and safety of combined buspirone and venlafaxine therapy in elderly patients diagnosed with geriatric depression accompanied by cognitive impairment. Methods: A 12-week, randomized controlled trial was conducted involving 170 elderly patients. Participants were randomized into two groups: one receiving venlafaxine alone (control group) and the other receiving a combination of venlafaxine and buspirone (experimental group). The primary analysis was performed using an Intent-to-Treat (ITT) approach with mixed-effects linear models to assess changes in depressive symptoms, cognitive function, and anxiety levels. A supplementary Per-Protocol (PP) analysis, utilizing repeated measures ANOVA, was also conducted. Results: The ITT analysis showed that the combination therapy significantly reduced depressive symptoms, as indicated by the HAMD-17 scores (p = 0.033 at week 12). Cognitive function, as measured by MoCA scores, also improved significantly in the experimental group by week 12 (p = 0.025). However, no statistically significant differences were observed in anxiety reduction between the groups (p = 0.127). The PP analysis confirmed these findings, demonstrating consistent improvements in depressive symptoms and cognitive function, particularly in those who completed the full course of treatment. The incidence of adverse events was comparable between groups, primarily mild and manageable symptoms like dry mouth, dizziness, and fatigue. Conclusion: The combination of buspirone and venlafaxine was found to be effective in reducing depressive symptoms and enhancing cognitive function in elderly patients with geriatric depression. However, the long-term benefits, especially regarding anxiety reduction, require further investigation. Future studies should consider larger sample sizes, longer follow-up periods, and the inclusion of placebo controls to fully assess the efficacy and safety of this treatment approach.

COMPARATIVE STUDY OF DRUGS IN TREATMENT OF SENILE DEPRESSION

A comparative study of treatment of depression:Mirtazapine vs.fluoxepine

Consensus of mirtazapine in treatment of depression

Efficacy and safety of olanzapine combined with fluoxetine in treatment of depression

A control study of citalopram vs. mirtazapine in senile depression

Clinical effects of escitalopram in the treatment of senile depression

A Study on Mirtazapine and Citalopram in the Treatment of Depression

A control study of Escitalopram and Venlafaxine in senile depression

The Efficacy and Safety of Mirtazapine and Fluoxetine for Depression:A Meta-analysis

Control study of mirtazapine and fluoxetine in therapy of depression

A Comparative Study of Citalopram and Maprotiline in Elderly Depressive Patients

To Observe the Therapeutic Effect of Escitalopram and Paroxetine on the Senile Depression

A Meta-analysis of Efficacy and Adverse Reactions of Paroxetine and Fluoxetine in Patients with Depression

Comparative study of Duloxetine combined with Mirtazapine, Venlafaxine combined with Mirtazapine in treatment of refractory depression

Randomized Controlled Clinical Trials of Remeron and Fluoxetine in Depressive Patients

Comparative Study of Efficacy and Safety of Mirtozapine and Doxepine in Treatment of Patients with Post-stroke Depression

Efficacy of fluoxetine combined with psychological intervention for treatment of depressive patients with insomnia

Assessing the efficacy and safety of combined buspirone and venlafaxine treatment in late-life depression accompanied by cognitive impairment: A randomized controlled trial

Comparisons of the Efficacy and Tolerability of Extended-Release Venlafaxine, Mirtazapine, and Paroxetine in Treatment-Resistant Depression: a Double-Blind, Randomized Pilot Study in a Chinese Population.

A Clinical Study of Venlafaxine in the Treatment of Anxiety in Elderly Hypertensive Patients with Anxiety

A controlled study in the treatment of depression with escitalopram and paroxetine